• Thelial is dedicated to epithelia

    Thelial is exclusively dedicated to epithelial indications

    • carcinoma (especially non-melanoma skin cancer).
    • epithelial barrier defects (initial focus orphan allergy indication).

    The mechanism of action we exploit is cell polarity modulation: Healthy cells are polar, loss of cell polarity is linked to disease and ageing – Thelial focuses on discovery and development of polarity modulating compounds to address mayor unmet market needs.

    theLiTE™ (Thelial – Live Targeted Epithelia) is our proprietary targeted drug discovery platform technology; screening a library of more than 2000 drug candidates we have discovered more than twenty epithelium targeted candidates, validating theLiTE™. Please request a non-confidential presentation on out technology and portfolio.

    For more information contact us

theLiTE publication

Together with our strategic partner Cristina Silva Pereira and collaborators we have used platform technology theLiTE to identify promising biological activities in novel secondary metabolites of fungi. The work was published in BMC Genomics in Spring 2016.

PubMed link


Preclinical development ongoing

In an ERC funded preclinical proof-of-concept study we team up with António Jacinto of CEDOC (Nova Medical School) and his group to test the efficacy of selected Thelial drug candidates in two orphan diseases characterised by tight junction defects.


In the News

Lab Times, one of the most popular Life Science journals in Europe, interviewed Thelial's team in fall 2014.

Follow this link to the article →